M
Massimo Santoro
Researcher at University of Turin
Publications - 185
Citations - 15848
Massimo Santoro is an academic researcher from University of Turin. The author has contributed to research in topics: Thyroid carcinoma & Thyroid. The author has an hindex of 66, co-authored 173 publications receiving 14778 citations. Previous affiliations of Massimo Santoro include Flanders Institute for Biotechnology & University of Eastern Piedmont.
Papers
More filters
Journal ArticleDOI
Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
Jianwei Wang,Jeffrey A. Knauf,Saswata Basu,Efisio Puxeddu,Hiroaki Kuroda,Massimo Santoro,Alfredo Fusco,James A. Fagin +7 more
TL;DR: Data indicate that RET/PTC is a weak tumor-initiating event and that TSH action is disrupted by this oncoprotein at several points, and also predict that secondary genetic or epigenetic changes are required for clonal expansion.
Journal ArticleDOI
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma.
Clara Ugolini,Riccardo Giannini,Cristiana Lupi,Giuliana Salvatore,Paolo Miccoli,Agnese Proietti,Rossella Elisei,Massimo Santoro,Fulvio Basolo +8 more
TL;DR: It is suggested that it is possible to find BRAF(V600E) in IM despite their extremely small (<1 mm) size, which is not a formal demonstration that IM can evolve into clinical PTC, but on these bases, patients with BRAFs with benign thyroid disease may need to be managed more carefully.
Journal Article
Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B
Domenico Salvatore,Rosa Marina Melillo,Carmen Monaco,Roberta Visconti,Gianfranco Fenzi,Giancarlo Vecchio,Alfredo Fusco,Massimo Santoro +7 more
TL;DR: It is concluded that the MEN2B mutation specifically potentiates the ability of Ret to autophosphorylate Y1062 and consequently to couple to the Ras/mitogen-activated protein kinase and the PI3K/Akt pathways.
Journal ArticleDOI
Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants
Teresa Guida,Suresh Anaganti,Livia Provitera,Richard W. Gedrich,Elizabeth H. Sullivan,Scott Wilhelm,Massimo Santoro,Francesca Carlomagno +7 more
TL;DR: Sorafenib might be a promising anticancer agent for patients carrying KIT and PDGFRβ gatekeeper mutations, as well as activation of AP1-responsive and cyclin D1 gene promoters, respectively.
Journal ArticleDOI
Dysregulated RET signaling in thyroid cancer.
TL;DR: The data about the mechanism of activation of downstream signal transduction pathways by RET oncoproteins is examined to advance the understanding of the processes underlying thyroid carcinoma formation.